Treatment · United States
Active-duty U.S. soldiers to receive psychedelic drugs for PTSD next year
Department of Defense-funded studies will provide MDMA-assisted therapy to active-duty service members with PTSD.
These are short summaries of research and reporting published elsewhere. We link to the original. Mental Hum does not report these stories.
Mental Hum is owned and operated by Dean Shaban
The Guardian reports that two DoD-funded studies will provide MDMA-assisted therapy to 186 active-duty service members with PTSD, the first major active-duty psychedelic therapy program.
The move reframes the post-Lykos psychedelic policy landscape and could shape future FDA submissions if outcomes are favorable.
Read the full Guardian report for the trial design.
Mental Hum is a reading list, not a publisher. The summary above is our own editorial framing; the reporting and analysis live at the source.